Form D · Biotechnology
Liquid Lung DX, Inc.
Fairfield, CT · CIK 0001771742
Offering snapshot reported Mar 27, 2019 · SEC filing
- Reported sold
- $70K Offering amount: $1M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- Mar 26, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 27, 2019 | Initial | $70,002 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-335763
Source: Form D, filed Mar 27, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Martin Keiser | Director, Executive |
| Martin Keiser, Jr. | Director |
| Patrick Lilley | Director |
| Sean Miot | Director |
| Steven Van Fleet | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
680 Stillson Road
Fairfield, CT, 06824
Fairfield, CT, 06824